fluticasone furoate/vilanterol vs Fluticasone propionate/salmeterol (Advair HFA)
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Asthma
Shared mechanisms: Beta-2 adrenergic receptor · Glucocorticoid receptor · Glucocorticoid receptor / Beta-2 adrenergic receptor · full Asthma pipeline
fluticasone furoate/vilanterol · Breo Ellipta
Marketed by GlaxoSmithKline
NCT01086384 · Phase 3 · completed
This was a randomized, triple-blind, active-controlled trial with approximately 2,019 treated participants. Its primary hard clinical endpoint—having one or more severe asthma exacerbations—favored fluticasone furoate/vilanterol and was statistically significant.
Reported efficacy
Number of Participants With 1 or More Severe Asthma Exacerbations (Baseline to Follow-up (up to 76 weeks of treatment)): Number of Participants With 1 or More Severe Asthma Exacerbations (Baseline to Follow-up (up to 76 weeks of treatment)): FF/VI 100/25 µg 154/1009 vs FF 100 µg 186/1010 (met)
Result source: NCT01086384
Fluticasone propionate/salmeterol (Advair HFA)
Marketed by GlaxoSmithKline
NCT00448435 · Phase 3 · completed
The 51 participants were randomized to treatment sequences and received an active comparator, but the trial was not blinded. Its primary morning PEF endpoint met the prespecified equivalence margin, while the endpoint was a physiologic surrogate rather than a hard clinical or endoscopic measure, supporting a moderate evidence grade.
Reported efficacy
Adjusted Mean Change From Baseline in Morning PEF (Peak Expiratory Flow) During the 4-week Treatment Periods (Crossover Period Weeks 1-4, and 7-10): Adjusted Mean Change From Baseline in Morning PEF (Peak Expiratory Flow) During the 4-week Treatment Periods (Crossover Period Weeks 1-4, and 7-10): SFC 50/100 Mcg/Day 14.3 Liters/minute (Standard Error 4.53) vs SLM 50 Mcg + FP 100 Mcg/Day 17.1 Liters/minute (Standard Error 4.53) (met)
Result source: NCT00448435
Results for Asthma
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | fluticasone furoate/vilanterol | Fluticasone propionate/salmeterol (Advair HFA) |
|---|---|---|
| Severe exacerbations, annualised rate | —Trial running · NCT05757102 | 1.9 vs 2.1vs Fluticasone PropionateNCT00452699 |
| Trough FEV1, change | 0.4 vs 0.2+0.2 vs placeboNCT011651388 other results
| —Not posted · NCT00646620 |
| ACQ-5, change | -1.2 vs -1.1vs FFNCT032481281 other result
| —Not posted · NCT00646620 |
| OCS dose reduction | —Trial running · NCT05757102 | —Not posted · NCT00646620 |
Severe exacerbations, annualised rate
- fluticasone furoate/vilanterol
- —Trial running · NCT05757102
- Fluticasone propionate/salmeterol (Advair HFA)
- 1.9 vs 2.1vs Fluticasone PropionateNCT00452699
Trough FEV1, change
- fluticasone furoate/vilanterol
- 0.4 vs 0.2+0.2 vs placeboNCT01165138
8 other results
- 0.4 vs 0.2 NCT01134042
- 0.5 vs 0.4 NCT01686633
- 0.3 vs 0.3 NCT01086384
- 0.3 vs 0.3 NCT01147848
- 0.4 vs 0.4 NCT01686633
- 0.3 vs 0.3 NCT03248128
- -0.1 vs -0.1 NCT02094937
- 0.3 vs 0.2 NCT03248128
- Fluticasone propionate/salmeterol (Advair HFA)
- —Not posted · NCT00646620
ACQ-5, change
- fluticasone furoate/vilanterol
- -1.2 vs -1.1vs FFNCT03248128
1 other result
- -1.3 vs -1.1 NCT03248128
- Fluticasone propionate/salmeterol (Advair HFA)
- —Not posted · NCT00646620
OCS dose reduction
- fluticasone furoate/vilanterol
- —Trial running · NCT05757102
- Fluticasone propionate/salmeterol (Advair HFA)
- —Not posted · NCT00646620
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
1 other shared endpoint and safety
Coverage. fluticasone furoate/vilanterol: 5 of 5 rows · Fluticasone propionate/salmeterol (Advair HFA): 5 of 5 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | fluticasone furoate/vilanterol | Fluticasone propionate/salmeterol (Advair HFA) |
|---|---|---|
| FEV1 absolute change · L | 0.019 vs 0 FP/S L @ 24wk100/25 mcg Once Dailya,b,c,d,e NCT02301975 · Phase 3 · registry result, not featured evidence show 1 more dose0.02 vs 0.014 FP/S L @ 24wk100/25 mcg Once Daily NCT02301975 · Phase 3 · registry result, not featured evidence | 0.2 vs 0.09 Fluticasone Propionate L @ 52wk250/50 mcg BIDb,c,d,e NCT00452699 · Phase 4 · registry result, not featured evidence |
| Dropout rate | —100/25 µgf NCT01086384 · Phase 3 show 16 more results—200/25 µg OD NCT01018186 · Phase 3 —100/25 µg OD NCT01018186 · Phase 3 — NCT03248128 · Phase 3 · Asthma · phase 3 10.9%100/25 µg OD NCT01165138 · Phase 3 7.2%200/25 µg OD NCT01686633 · Phase 3 9.2%100/25 µg OD NCT01686633 · Phase 3 14.2%200/25 µg OD NCT01134042 · Phase 3 · combination · Asthma · phase 3 —100/25 µg OD NCT01147848 · Phase 3 · Asthma · phase 3 —100/25 µg QD NCT02730351 · Phase 4 · registry result, not featured evidence 6.2%100/25 mcg Once Daily NCT02301975 · Phase 3 · registry result, not featured evidence —100 mcg once daily NCT02094937 · Phase 3 · registry result, not featured evidence —100 mcg once daily NCT02094937 · Phase 3 · registry result, not featured evidence —100/25 mcg once daily NCT02094937 · Phase 3 · registry result, not featured evidence · combination 14.4%100/25 µg Once Daily NCT01498679 · Phase 3 · registry result, not featured evidence 12.3%200/25 µg Once Daily NCT01498653 · Phase 3 · registry result, not featured evidence · Asthma · phase 3 —100 µg/25 µg NCT01453023 · Phase 2 · registry result, not featured evidence | —50/100 mcg/dayg NCT00448435 · Phase 3 · Asthma · phase 3 show 3 more results—50/100 mcg/day NCT00448435 · Phase 3 · Asthma · phase 3 26.5%250/50 mcg BID NCT00452699 · Phase 4 · registry result, not featured evidence 0% NCT00449046 · Phase 3 · registry result, not featured evidence |
| Discontinued due to AEs | —100/25 µgf NCT01086384 · Phase 3 show 16 more results—200/25 µg OD NCT01018186 · Phase 3 —100/25 µg OD NCT01018186 · Phase 3 — NCT03248128 · Phase 3 · Asthma · phase 3 1%100/25 µg OD NCT01165138 · Phase 3 0.9%200/25 µg OD NCT01686633 · Phase 3 0.9%100/25 µg OD NCT01686633 · Phase 3 3.6%200/25 µg OD NCT01134042 · Phase 3 · combination · Asthma · phase 3 —100/25 µg OD NCT01147848 · Phase 3 · Asthma · phase 3 —100/25 µg QD NCT02730351 · Phase 4 · registry result, not featured evidence 1.6%100/25 mcg Once Daily NCT02301975 · Phase 3 · registry result, not featured evidence —100 mcg once daily NCT02094937 · Phase 3 · registry result, not featured evidence —100 mcg once daily NCT02094937 · Phase 3 · registry result, not featured evidence —100/25 mcg once daily NCT02094937 · Phase 3 · registry result, not featured evidence · combination 2.6%100/25 µg Once Daily NCT01498679 · Phase 3 · registry result, not featured evidence 1.3%200/25 µg Once Daily NCT01498653 · Phase 3 · registry result, not featured evidence · Asthma · phase 3 —100 µg/25 µg NCT01453023 · Phase 2 · registry result, not featured evidence | —50/100 mcg/dayg NCT00448435 · Phase 3 · Asthma · phase 3 show 3 more results—50/100 mcg/day NCT00448435 · Phase 3 · Asthma · phase 3 3.3%250/50 mcg BID NCT00452699 · Phase 4 · registry result, not featured evidence — NCT00449046 · Phase 3 · registry result, not featured evidence |
| Serious AEs | 4.1%100/25 µgf NCT01086384 · Phase 3 show 16 more results0.5%200/25 µg OD NCT01018186 · Phase 3 1.5%100/25 µg OD NCT01018186 · Phase 3 1.1% NCT03248128 · Phase 3 · Asthma · phase 3 0%100/25 µg OD NCT01165138 · Phase 3 0.3%200/25 µg OD NCT01686633 · Phase 3 1.2%100/25 µg OD NCT01686633 · Phase 3 3%200/25 µg OD NCT01134042 · Phase 3 · combination · Asthma · phase 3 1%100/25 µg OD NCT01147848 · Phase 3 · Asthma · phase 3 1.4%100/25 µg QD NCT02730351 · Phase 4 · registry result, not featured evidence 1.2%100/25 mcg Once Daily NCT02301975 · Phase 3 · registry result, not featured evidence —100 mcg once daily NCT02094937 · Phase 3 · registry result, not featured evidence 0.8%100 mcg once daily NCT02094937 · Phase 3 · registry result, not featured evidence 0%100/25 mcg once daily NCT02094937 · Phase 3 · registry result, not featured evidence · combination 1.3%100/25 µg Once Daily NCT01498679 · Phase 3 · registry result, not featured evidence 0.6%200/25 µg Once Daily NCT01498653 · Phase 3 · registry result, not featured evidence · Asthma · phase 3 0%100 µg/25 µg NCT01453023 · Phase 2 · registry result, not featured evidence | 0%50/100 mcg/dayg NCT00448435 · Phase 3 · Asthma · phase 3 show 3 more results0%50/100 mcg/day NCT00448435 · Phase 3 · Asthma · phase 3 4.6%250/50 mcg BID NCT00452699 · Phase 4 · registry result, not featured evidence — NCT00449046 · Phase 3 · registry result, not featured evidence |
| Most frequent reported AEs | 100/25 µgf headache 18.6% nasopharyngitis 15.4% upper respiratory tract infection 7.2% NCT01086384 · Phase 3 show 15 more results200/25 µg OD headache 17.3% upper respiratory tract infection 14.9% nasopharyngitis 9.4% NCT01018186 · Phase 3 100/25 µg OD headache 19.4% upper respiratory tract infection 16.9% nasopharyngitis 12.4% NCT01018186 · Phase 3 nasopharyngitis 10.4% upper respiratory tract infection 7% rhinitis allergic 4.2% NCT03248128 · Phase 3 · Asthma · phase 3 200/25 µg OD headache 8.4% nasopharyngitis 7.2% upper respiratory tract infection 2% NCT01686633 · Phase 3 100/25 µg OD headache 8.4% nasopharyngitis 6.4% upper respiratory tract infection 2.3% NCT01686633 · Phase 3 200/25 µg OD nasopharyngitis 12.7% headache 5.6% bronchitis 3.6% NCT01134042 · Phase 3 · combination · Asthma · phase 3 100/25 µg OD nasopharyngitis 11.4% headache 8.4% upper respiratory tract infection 6.2% NCT01147848 · Phase 3 · Asthma · phase 3 100/25 µg QD upper respiratory tract infection 6.8% NCT02730351 · Phase 4 · registry result, not featured evidence 100/25 mcg Once Daily nasopharyngitis 12.1% headache 8.1% bronchitis 4% NCT02301975 · Phase 3 · registry result, not featured evidence 100 mcg once daily nasopharyngitis 17.9% NCT02094937 · Phase 3 · registry result, not featured evidence 100/25 mcg once daily nasopharyngitis 15.6% NCT02094937 · Phase 3 · registry result, not featured evidence · combination 100/25 µg Once Daily upper respiratory tract infection 7.2% (placebo 9.1%) headache 4.6% (placebo 1.9%) nasopharyngitis 4.6% (placebo 8.4%) NCT01498679 · Phase 3 · registry result, not featured evidence 200/25 µg Once Daily upper respiratory tract infection 8.4% nasopharyngitis 3.9% rhinitis allergic 3.2% NCT01498653 · Phase 3 · registry result, not featured evidence · Asthma · phase 3 100 µg/25 µg bronchitis 4% conjunctivitis 4% headache 4% NCT01453023 · Phase 2 · registry result, not featured evidence | 50/100 mcg/dayg upper respiratory tract inflammation 13.7% nasopharyngitis 3.9% stomatitis 3.9% NCT00448435 · Phase 3 · Asthma · phase 3 show 3 more results50/100 mcg/day upper respiratory tract inflammation 34% gastroenteritis 14% nasopharyngitis 14% NCT00448435 · Phase 3 · Asthma · phase 3 250/50 mcg BID upper respiratory tract infection 20.3% headache 18.3% nasopharyngitis 17.6% NCT00452699 · Phase 4 · registry result, not featured evidence asthma 20% bronchitis 20% laryngopharyngitis 20% NCT00449046 · Phase 3 · registry result, not featured evidence |
Notes
- aThis study reports multiple eligible drug arms; no representative arm has been reviewed.
- bTrial phases differ: Phase 3 versus Phase 4.
- cPopulation comparability has not been reviewed for both studies.
- dTreatment context has not been resolved for both arms.
- eAssessment timepoints differ: 24 weeks versus 52 weeks.
- fPopulation comparability has not been reviewed for 13 of these studies.
- gPopulation comparability has not been reviewed for 2 of these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
fluticasone furoate/vilanterol
show 8 more results
show 1 more result
show 6 more results
show 1 more result
show 1 more result
show 1 more result
show 3 more results
show 4 more results
show 3 more results
show 4 more results
+ 18 further endpoints in the CSV export.
Fluticasone propionate/salmeterol (Advair HFA)
+ 11 further endpoints in the CSV export.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: fluticasone furoate/vilanterol's landscape · Fluticasone propionate/salmeterol (Advair HFA)'s landscape